{"id":23880,"date":"2022-12-02T22:58:00","date_gmt":"2022-12-02T14:58:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23880"},"modified":"2025-01-29T23:11:20","modified_gmt":"2025-01-29T15:11:20","slug":"luye-pharma-partners-with-nhwa-and-fine-hin-to-commercialize-toludesvenlafaxine","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23880","title":{"rendered":"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine"},"content":{"rendered":"\n

China-based Luye Pharma Group (HKG: 2186<\/a>), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262<\/a>), and Beijing Fine Hin Mobile Medical Technology Co., Ltd have agreed to leverage their respective expertise, platform advantages, and commercialization resources to bolster the commercialization of Luye\u2019s Category 1 chemical drug toludesvenlafaxine (LY03005), an extended-release treatment for depression. No financial details were disclosed.<\/p>\n\n\n\n

Toludesvenlafaxine: Mechanism and Clinical Studies<\/strong>
Toludesvenlafaxine is a new molecular entity with a novel mechanism of action, described as essentially a serotonin (5-HT), norepinephrine (NE), and dopamine (DA) triple reuptake inhibitor (SNDRI\/TRI). Clinical studies have confirmed that it can act as a comprehensive treatment for depression, significantly improve patients’ emotional symptoms and cognitive ability, and promote the recovery of social functions. In addition, it has good safety and tolerance, does not cause drowsiness, and does not affect sexual function, weight, or lipid metabolism. The drug is awaiting regulatory decisions in the US and has completed a Phase I study on depression in Japan. A Phase III study in generalized anxiety disorder (GAD) is also underway in China.<\/p>\n\n\n\n

Partnership Background<\/strong>
Nhwa Pharma, a central nervous system (CNS) specialist founded in 1978, backed Fine Hin Mobile Medtech with RMB 50 million (USD 7 million) alongside medical resources in the latter\u2019s angel funding round in 2016. Founded in 2015, Fine Hin is the largest CNS and mental health Internet medical service platform in China, focusing on providing digital diagnosis and treatment services for patients with mental disorders.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,93],"tags":[30,87,3389,1023,219,122,1472,79,1471,2250],"class_list":["post-23880","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-digital","tag-biotech","tag-chronic-disease","tag-fine-hin-mobile-medical-technology","tag-hkg-2186","tag-luye-pharma","tag-mobile-health-app","tag-nhwa-pharmaceutical","tag-online-hospitals","tag-she-002262","tag-telemedicine"],"yoast_head":"\nLuye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing Fine Hin Mobile Medical Technology Co., Ltd have agreed to leverage their respective expertise, platform advantages, and commercialization resources to bolster the commercialization of Luye\u2019s Category 1 chemical drug toludesvenlafaxine (LY03005), an extended-release treatment for depression. No financial details were disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23880\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23880\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-02T14:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T15:11:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23880#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23880\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine\",\"datePublished\":\"2022-12-02T14:58:00+00:00\",\"dateModified\":\"2025-01-29T15:11:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23880\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Chronic disease\",\"Fine Hin Mobile Medical Technology\",\"HKG: 2186\",\"Luye Pharma\",\"Mobile health \\\/ APP\",\"Nhwa Pharmaceutical\",\"Online hospitals\",\"SHE: 002262\",\"Telemedicine\"],\"articleSection\":[\"Company\",\"Deals\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23880#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23880\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23880\",\"name\":\"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-02T14:58:00+00:00\",\"dateModified\":\"2025-01-29T15:11:20+00:00\",\"description\":\"China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing Fine Hin Mobile Medical Technology Co., Ltd have agreed to leverage their respective expertise, platform advantages, and commercialization resources to bolster the commercialization of Luye\u2019s Category 1 chemical drug toludesvenlafaxine (LY03005), an extended-release treatment for depression. No financial details were disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23880#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23880\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23880#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine - Insight, China's Pharmaceutical Industry","description":"China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing Fine Hin Mobile Medical Technology Co., Ltd have agreed to leverage their respective expertise, platform advantages, and commercialization resources to bolster the commercialization of Luye\u2019s Category 1 chemical drug toludesvenlafaxine (LY03005), an extended-release treatment for depression. No financial details were disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23880","og_locale":"en_US","og_type":"article","og_title":"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23880","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-02T14:58:00+00:00","article_modified_time":"2025-01-29T15:11:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23880#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23880"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine","datePublished":"2022-12-02T14:58:00+00:00","dateModified":"2025-01-29T15:11:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23880"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Chronic disease","Fine Hin Mobile Medical Technology","HKG: 2186","Luye Pharma","Mobile health \/ APP","Nhwa Pharmaceutical","Online hospitals","SHE: 002262","Telemedicine"],"articleSection":["Company","Deals","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23880#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23880","url":"https:\/\/flcube.com\/?p=23880","name":"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-02T14:58:00+00:00","dateModified":"2025-01-29T15:11:20+00:00","description":"China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing Fine Hin Mobile Medical Technology Co., Ltd have agreed to leverage their respective expertise, platform advantages, and commercialization resources to bolster the commercialization of Luye\u2019s Category 1 chemical drug toludesvenlafaxine (LY03005), an extended-release treatment for depression. No financial details were disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23880#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23880"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23880#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23880"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23880\/revisions"}],"predecessor-version":[{"id":23882,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23880\/revisions\/23882"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}